Urgent Care Market Grows Up

The estimated 9,400 Urgent care centers (UCCs) in the United States sold over 15 billion dollars worth of services in 2013.  These medical clinics in a free-standing location or strip-mall provide an increasingly critical option between a physician’s office and a hospital emergency room.  The estimate was made in Kalorama’s U.S. Market for Urgent Care Centers (http://www.kaloramainformation.com/Urgent-Care-Centers-8430284/).

Ebola Threat Leads To Fast Track Vaccine Efforts

Companies who had vaccine programs for Ebola are speeding them up in the wake of the focus on this disease.  Many concerns are aligning with the WHO’s Ebola Response Roadmap, including its call to fast-track access to treatment and vaccine options to address the urgent situation.  Kalorama covers the vaccine market including future forecasts in its recent report on the industry.  

Medical Device Start-Up Flight to Europe and its Market Implications

Future upsides to the global medical device market may increasingly originate in Europe as many start-ups seek initial market approval within the European Union (EU). Recent criticism of the U.S. FDA has been preoccupied with the relative complexity of clinical trial plans in the United States. At a recent conference, Mark Deem, managing partner of medical device incubator The Foundry LLC, noted the FDA’s deficiencies relating to his issue:

UK Tackles Flu With Children Before It Reaches Adults

Two- to four-year-olds in the UK are for the second time being offered an egg-based nasal vaccine, and the UK will expand to older children.    The intention is to prevent influenza (flu) in hopes of not just protecting children from getting flu, but also of stopping the disease spreading from them to their family, caregivers and the wider population.  As we've indicated in our report on Biopharmaceutical and Vaccine production, http://www.kaloramainformation.com/Biopharmaceutical-Vaccine-Production-8


Companion Diagnostics Alliances Mount – Clarient and GSK Deal Visited

In yet another sign that the ranks of recruitment are expanding in personalized medicine’s fight against cancer, GE Healthcare announced an agreement between its subsidiary Clarient Diagnostic Services and pharmaceutical giant GlaxoSmithKline (GSK). With GE Healthcare, the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories.


Subscribe to Kalorama Information Home RSS